Literature DB >> 9856418

The feasibility of long-term treatment of polycystic ovary syndrome with GnRH-agonists.

S L Berga1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9856418     DOI： 10.1007/BF03350789

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  7 in total

1.  Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.

Authors:  C L Pastor; M L Griffin-Korf; J A Aloi; W S Evans; J C Marshall
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

2.  Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome.

Authors:  C Gilling-Smith; H Story; V Rogers; S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

3.  Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.

Authors:  E A Ruchhoft; K E Elkind-Hirsch; R Malinak
Journal:  Fertil Steril       Date:  1996-07       Impact factor: 7.329

4.  Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation.

Authors:  T L Daniels; S L Berga
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

5.  Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.

Authors:  M T Korytkowski; M Mokan; M J Horwitz; S L Berga
Journal:  J Clin Endocrinol Metab       Date:  1995-11       Impact factor: 5.958

Review 6.  Therapeutic use of gonadotropin-releasing hormone agonists in polycystic ovarian syndrome.

Authors:  V Markussis; M H Goni; G Tolis
Journal:  Ann N Y Acad Sci       Date:  1993-05-28       Impact factor: 5.691

7.  Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.

Authors:  M Filicori; E Campaniello; L Michelacci; A Pareschi; P Ferrari; G Bolelli; C Flamigni
Journal:  J Clin Endocrinol Metab       Date:  1988-02       Impact factor: 5.958
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.